Omeros stock tumbles after EU panel rejects Yartemlea

Investing.com -- Omeros Corporation (NASDAQ: OMER) fell 14% Friday morning after the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion for Yartemlea.

The CHMP recommended against approval of Yartemlea (narsoplimab) for the treatment of adults and children from two years of age with haematopoietic stem cell transplant-associated thrombotic microangiopathy. Thrombotic microangiopathy is a serious and potentially life-threatening complication following HSCT, a procedure where the patient's bone marrow is replaced by stem cells from a donor to form new bone marrow that produces healthy cells.

The committee also adopted negative opinions for two other medicines: Tacquell (autologous melanoma-derived tumour infiltrating lymphocytes, ex vivo-expanded), for the treatment of advanced melanoma, and Xervyteg (allogeneic faecal microbiota, pooled), for the treatment of acute graft-versus-host disease.

You May Also Be Interested In

• Bytedance Gets $30b Loan, Asia's Second-largest This Year - Bloomberg
• Citi reiterates Buy rating on Baidu with $166 price target, Opens 30 Day Upside Catalyst Watch
• Sempra Energy (SRE) Declares $0.6575 Quarterly Dividend; 3.1% Yield